Patient Perceptions of Dopaminergic Therapy Withdrawal in Parkinson’s disease
Objective: To survey Parkinson’s disease (PD) patients regarding their willingness and experience in withdrawal of their dopaminergic medications. Background: Parkinson’s disease patients are asked to…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…The role of immediate communication by text or phone calls by patients with fluctuation motor complaints in Parkinson’s disease and other movement disorders
Objective: To evaluate the usefulness of immediate response by phone/text messages to questions of patients with Parkinson’s disease and other movement disorders Background: Communicating with…Efficacy of ND0612 for nocturnal problems and early morning OFF
Objective: ND012 is a drug-device combination delivering liquid L-dopa/carbidopa (LD/CD) via continuous SC infusion. This secondary analysis evaluated the efficacy of 2 dosing regimens (R1:…The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings
Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…The Levodopa Response Trial and the Parkinson Disease Digital Biomarker Challenge: Monitoring symptoms of Parkinson’s disease in the lab and home using wearable sensors
Objective: To leverage a community of researchers and shared wearable data to develop algorithms to estimate the severity of PD specific symptoms. Background: People with…The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease
Objective: Describe the design and baseline characteristics of a long-term (1 year) study of 2 ND0612 dose regimens, with emphasis on systemic and local safety…Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia: Evaluation of clinical response with the wearable PKG (Personal Kinetigraph) watch
Objective: To determine the effect of bedtime high-dose amantadine extended release (Gocovri) in 50 consecutive patients experiencing motor fluctuations and dyskinesia. Background: Amantadine extended release…Safinamide effect in patients with Parkinson’s disease and deep brain stimulation
Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 24
- Next Page »